Skip to main content

Advertisement

Table 2 Clinical characteristics of study participants

From: Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana

Characteristics N = 300 n, %
Duration on TDF (study endpoint/censoring), median (IQR) years 2.9 [2.3–3.4]
Baseline CrCl rate, median (IQR), mL/min 76.8 [58.3–105.4]
WHO HIV stage
 Stage I 52 (17.3)
 Stage II 76 (25.3)
 Stage III 134 (44.7)
 Stage IV 38 (12.7)
HIV type
 Type I 284 (94.7)
 Type II 16 (5.3)
ART regimen administered
 NNRTI-based 291 (97.0)
 PI-based 9 (3.0)
Baseline CD4 count (cells/mm3)
  < 150 134 (44.7)
 150–250 58 (19.3)
  > 250 108 (36.0)
Adverse event
 Present 47 (15.7)
 Absent 253 (84.3)
Co-morbiditiesa
 None 220 (68.0)
 Pregnancy 22 (7.3)
 Anaemia 10 (3.3)
 Tuberculosis 10 (3.3)
 Hypertension 9 (3.0)
 Malaria 9 (3.0)
 Pneumonia 8 (2.7)
 Hepatitis 7 (2.3)
 Cerebral toxoplasmosis 6 (2.0)
 Urinary tract infection 5 (1.7)
 Asthma 2 (0.7)
 Diabetes 2 (0.7)
 Achalasia 1 (0.3)
 Deep vein thrombosis 1 (0.3)
 Gouty arthritis 1 (0.3)
 Psychosis 1 (0.3)
Co-medicationa
 None 260 (86.7)
 Antibiotic 21 (7.0)
 Antihypertensive 13 (4.3)
 Haematinic 5 (1.7)
 Antiallergic 3 (1.0)
 Anticoagulant 2 (0.7)
 Antidiabetic 2 (0.7)
 Antigout 1 (0.3)
  1. ART: Antiretroviral therapy; CrCl: creatinine clearance rate; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; TDF: tenofovir
  2. a% May not add up to 100